CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, the developer of the leading liquid biopsy platform that enables non-invasive diagnosis of disease states, aiming to obviate the need for tissue ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, today announced the publication of new data demonstrating the ability ...

Boston, MA, June 22, 2017 (GLOBE NEWSWIRE) -- John Boyce, President and CEO of Exosome Diagnostics Inc., a leader in the liquid biopsy space, presented a talk entitled “The True Liquid Biopsy” during ...

The exosome diagnostic and therapeutic market was valued at US$ 41.6.33 million in 2019 and is expected to grow at a CAGR of 32.2% from 2020 to 2027 to reach US$ 358.91 million 2027. According to The ...

Waltham, MA, March 21, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., is thrilled to announce the appointment of Dr. Grannum Sant as Head of Medical Affairs. As an internationally recognized ...

MINNEAPOLIS, March 18, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that the General Services Administration (GSA) has awarded an unlimited 10-year reimbursement contract ...

Exosome diagnostics and therapeutics hold promise for treating neurodegenerative diseases like Alzheimer's and Parkinson's, breast, prostate, liver, and lung cancer, and cardiovascular dysfunction ...

Bio-Techne Corporation (NASDAQ: TECH) today announced that Exosome Diagnostics, a Bio-Techne brand, has reported results from a proof-of-concept study for a novel exosome-based platform that could ...